The current and changing role of glucagon-like peptide-1 receptor agonists in knee osteoarthritis.
作者信息
Holleman Anne D, Katz Jeffrey N
机构信息
Department of Orthopedics, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
出版信息
Osteoarthr Cartil Open. 2025 Apr 12;7(3):100611. doi: 10.1016/j.ocarto.2025.100611. eCollection 2025 Sep.
Abstract
摘要
相似文献
1
The current and changing role of glucagon-like peptide-1 receptor agonists in knee osteoarthritis.胰高血糖素样肽-1受体激动剂在膝关节骨关节炎中不断变化的当前作用
Osteoarthr Cartil Open. 2025 Apr 12;7(3):100611. doi: 10.1016/j.ocarto.2025.100611. eCollection 2025 Sep.
2
The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists.GLP-1 受体激动剂治疗患者的骨关节炎进展和全关节置换术的五年发生率。
J Arthroplasty. 2024 Oct;39(10):2433-2439.e1. doi: 10.1016/j.arth.2024.06.008. Epub 2024 Jun 8.
3
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.胰高血糖素样肽-1 受体激动剂作为一种通过减轻体重介导的膝骨关节炎的疾病修正治疗：来自上海骨关节炎队列研究的结果。
Ann Rheum Dis. 2023 Sep;82(9):1218-1226. doi: 10.1136/ard-2023-223845. Epub 2023 May 31.
4
Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon-like peptide-1 agonists.解开关联之纽带：肥胖、骨关节炎与炎症通路的交叉点，重点关注胰高血糖素样肽-1激动剂
Clin Obes. 2025 Feb;15(1):e12700. doi: 10.1111/cob.12700. Epub 2024 Aug 16.
5
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohorts Retrospective Study.2型糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂的比较及骨关节炎和关节置换术风险：一项倾向评分匹配队列回顾性研究
Diabetes Metab Res Rev. 2025 Jul;41(5):e70051. doi: 10.1002/dmrr.70051.
6
The Impact of Contemporary Glucagon-like Peptide-1 Receptor Agonists on the Onset, Severity, and Conversion to Arthroplasty in Hip and Knee Osteoarthritis.当代胰高血糖素样肽-1受体激动剂对髋膝关节骨关节炎发病、严重程度及关节置换转化的影响
Orthop J Sports Med. 2025 Jan 13;13(1):23259671241297157. doi: 10.1177/23259671241297157. eCollection 2025 Jan.
7
Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.用于髋膝关节骨关节炎患者医学监督下减肥的胰高血糖素样肽受体-1激动剂：关节置换外科医生的关键考量
Arthroplast Today. 2024 Jun 27;27:101327. doi: 10.1016/j.artd.2024.101327. eCollection 2024 Jun.
8
Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study.胰高血糖素样肽-1受体激动剂疗法降低2型糖尿病患者膝骨关节炎风险及全膝关节置换风险：一项基于全国人群的队列研究
Medicine (Baltimore). 2025 Feb 7;104(6):e41243. doi: 10.1097/MD.0000000000041243.
9
Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.胰高血糖素样肽-1 受体激动剂：临床药理学的叙述性综述及其对围手术期实践的影响。
Anaesthesia. 2024 Jul;79(7):735-747. doi: 10.1111/anae.16306. Epub 2024 May 13.
10
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.基于肠降血糖素的 2 型糖尿病治疗药物：对疗效、安全性和患者满意度的直接比较的综述。
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
本文引用的文献
1
Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.胰高血糖素样肽-1受体激动剂在骨关节炎中的作用：临床前和人体研究的系统评价
Osteoarthr Cartil Open. 2025 Jan 28;7(1):100567. doi: 10.1016/j.ocarto.2025.100567. eCollection 2025 Mar.
2
Mapping the effectiveness and risks of GLP-1 receptor agonists.绘制胰高血糖素样肽-1受体激动剂的有效性和风险图谱。
Nat Med. 2025 Mar;31(3):951-962. doi: 10.1038/s41591-024-03412-w. Epub 2025 Jan 20.
3
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.减肥对去脂体重、肌肉、骨骼和造血健康的影响：对旨在减少脂肪和保留瘦体重的新兴药物治疗的意义。
Metabolism. 2024 Dec;161:156057. doi: 10.1016/j.metabol.2024.156057. Epub 2024 Oct 30.
4
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.每周一次司美格鲁肽治疗肥胖合并膝关节骨关节炎患者的疗效
N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664.
5
Weight Loss-Induced Muscle Mass Loss.体重减轻导致的肌肉量减少。
JAMA. 2024 Sep 23. doi: 10.1001/jama.2024.17212.
6
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes.利拉鲁肽，一种胰高血糖素样肽-1 受体激动剂，通过抑制 AGEs 诱导的软骨细胞中晚期糖基化终产物受体信号通路改善炎症和细胞凋亡。
BMC Musculoskelet Disord. 2024 Jul 30;25(1):601. doi: 10.1186/s12891-024-07640-6.
7
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.基于胰高血糖素样肽-1 的治疗方法和缓解策略对去脂体重的影响。
Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.
8
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.通过运动、胰高血糖素样肽-1受体激动剂或两者联合进行健康体重维持，随后一年不进行治疗：一项随机安慰剂对照试验的治疗后分析
EClinicalMedicine. 2024 Feb 19;69:102475. doi: 10.1016/j.eclinm.2024.102475. eCollection 2024 Mar.
9
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.胰高血糖素样肽-1 受体激动剂作为一种通过减轻体重介导的膝骨关节炎的疾病修正治疗：来自上海骨关节炎队列研究的结果。
Ann Rheum Dis. 2023 Sep;82(9):1218-1226. doi: 10.1136/ard-2023-223845. Epub 2023 May 31.
10
Effect of Diet and Exercise on Knee Pain in Patients With Osteoarthritis and Overweight or Obesity: A Randomized Clinical Trial.饮食和运动对超重或肥胖的骨关节炎患者膝关节疼痛的影响：一项随机临床试验。
JAMA. 2022 Dec 13;328(22):2242-2251. doi: 10.1001/jama.2022.21893.
Zotero 插件